Northwest Biotherapeutics

Northwest Biotherapeutics has closed a $4.9 million convertible note with YA II PN, Ltd. (managed by Yorkville Advisors) to bridge acute liquidity shortfalls. The unsecured, non‑interest‑bearing note runs for 12 months, is issued with a 5% original issue discount and can be converted by the holder prior to maturity into shares at a small discount. In addition, there is a voluntary standby equity purchase agreement of up to $50 million within 24 months and a warrant of up to $2 million at $0.205 per share. The proceeds are for general corporate purposes and to support the lead product; however, the company has a very weak balance sheet (current ratio 0.07; levered FCF -$49.4 million) and the stock fell nearly 40% over six months. » Más en de.investing.com

CTO Dr. Marnix Bosch of Northwest Biotherapeutics will present analyses of survival extension from DCVax-L using propensity score matching at the 2026 annual meeting of the British Neuro-Oncology Society. The presentation, titled “DCVax-L Associated Survival Extension Assessed Through Propensity Score Matching Analyses,” will take place on Friday at 10:00 GMT; the slides will be published afterward on the company website. Northwest is a clinical-stage biotech with a completed phase III trial (331 patients) of DCVax-L and an ongoing regulatory review in the United Kingdom. The stock trades near its 52-week low at $0.18; data show high cash outflows and continued lack of profitability. » Más en de.investing.com

Northwest Biotherapeutics has completed the acquisition of Advent BioServices; the transaction closed on October 24, 2025. The purchase price is about $1.9 million, payable in installments over two years with 7.5% interest on the unpaid balance, and Northwest assumes roughly $8.3 million of net liabilities for services previously provided. The deal is classified as a related-party transaction because CEO Linda Powers is the controlling member of the seller; the SEC granted an exemption under Rule 3-13. The company also settled a Delaware lawsuit, with insurers paying $2.25 million and 17% of the disputed 2020 option grants being cancelled. » Más en de.investing.com